Dr. Yuxuan Wu is the co-founder and CEO of YolTech Therapeutics, where he drives the development of next-generation in vivo gene-editing therapies using LNP-mRNA delivery. To date, YolTech has advanced multiple therapeutic programs into clinical stage, with a diversified pipeline spanning genetic, metabolic, cardiovascular diseases.

Prior to YolTech, Dr. Wu developed BRL-101, a CRISPR-based therapy for patients with transfusion-dependent β-thalassemia, which achieved excellent efficacy (Nature Medicine, 2022). From 2015 to 2018, he worked at Harvard Medical School, where he contributed to the development of a CRISPR/Cas9-based editing system for hematopoietic stem cells to treat hemoglobin disorders by reactivating fetal hemoglobin expression (Nature Medicine, 2019, 2020).

Dr. Wu holds a Ph.D. in Biology from Wuhan University.

Prior to Yoltech, Jessie spent six years at Legend Biotech, serving as Vice President of Finance and Investor Relations, and Interim CFO with responsibility of budgetary oversight, achieving profitability targets, long-range financial planning. Throughout her tenure, Jessie was instrumental in executing Legend's capital markets strategy. Her Wall Street acumen helped craft the company's foundational investment thesis.

Jessie brings extensive biotech sector expertise to Yoltech. She previously served as Vice President of Investor Relations and Corporate Finance at Rocket Pharmaceuticals, where she led a $115 million public equity offering, and held biopharma equity research roles at Bank of America Merrill Lynch and Wells Fargo Securities. Her career foundation includes a formative ten-year tenure at JPMorgan spanning both the U.S. and Asian markets.

Jessie earned her MBA from Columbia Business School and a B.S. in Finance and Business Administration from Carnegie Mellon University.

Dr. Patel brings more than 18 years of experience in clinical development, medical affairs, and pharmacovigilance, with a focus on rare diseases, immunology, and cell and gene therapy at leading global biopharmaceutical and biotechnology companies. He most recently served as Interim Head of U.S. Clinical Development at Legend Biotech, where he built and led a team overseeing early-stage in vivo and late-stage programs, including multiple Phase 3 studies. He served as clinical lead across programs and played a key role in multiple U.S. and EU regulatory submissions. Previously, Dr. Patel held senior clinical development roles at GSK, including in early clinical development for T cell and gene therapy in oncology and late-stage rare disease programs using CD34+ stem cell gene therapy, and served as Medical Director for AAV gene therapy in rare diseases at Freeline. Earlier in his career, he held roles in medical affairs and pharmacovigilance at GSK, Novartis, and Johnson & Johnson. 

Dr. Patel is a GMC-registered physician with a CCT in Pharmaceutical Medicine. He earned a BM BCh from the University of Oxford and a BA and MA from the University of Cambridge.

As Chief Development and Technical Officer at YolTech, Dr. Emma Wang orchestrates the strategic advancement of the company’s core platforms and therapeutic programs. With over a decade of expertise in the pharmaceutical and biotech sectors, Emma previously spent more than five years specializing in mRNA/LNP drug product development and CMC strategy. At YolTech, she now integrates these disciplines, directing a multidisciplinary organization that spans R&D, CMC strategy, global manufacturing, regulatory affairs, and the transition into early-stage clinical trials. She holds a B.Eng and M.Eng in Chemical Engineering from McGill University in Canada and Ph.D. in Chemistry from Max Planck Institute for Polymer Research in Germany.

Dr. Yuxuan Wu is the co-founder and CEO of YolTech Therapeutics, where he drives the development of next-generation in vivo gene-editing therapies using LNP-mRNA delivery. To date, YolTech has advanced multiple therapeutic programs into clinical stage, with a diversified pipeline spanning genetic, metabolic, cardiovascular diseases.

Prior to YolTech, Dr. Wu developed BRL-101, a CRISPR-based therapy for patients with transfusion-dependent β-thalassemia, which achieved excellent efficacy (Nature Medicine, 2022). From 2015 to 2018, he worked at Harvard Medical School, where he contributed to the development of a CRISPR/Cas9-based editing system for hematopoietic stem cells to treat hemoglobin disorders by reactivating fetal hemoglobin expression (Nature Medicine, 2019, 2020).

Dr. Wu holds a Ph.D. in Biology from Wuhan University.

Dr. Tong has been serving as the Director since September 2023. Prior to joining Yoltech, Dr. Tong served successively as an investment assistant and an executive assistant to the president at YiFang Technology Group (Beijing) Co., Ltd. from November 2009 to May 2012. He served as a senior investment manager at Govtor Mingly Growth Venture Capital Co., Ltd. from May 2012 to November 2012. He worked at Shanghai Mingxin Equity Investment Management Partnership Enterprise (Limited Partnership) from December 2012 to May 2014. He served as a vice president of investment at Suzhou Decheng Shengke Enterprise Management Co., Ltd. Shanghai Branch from May 2014 to May 2017. He served as a director at Insight Lifetech Co., Ltd., a company listed on the Shanghai Stock Exchange (stock code: 688712) from June 2021 to December 2025. He also successively served as head of compliance and risk control at Shanghai Dejia Chengyu Private Equity Fund Management Partnership (Limited Partnership) from May 2017 to October 2023, where he has been serving as a general partner and managing partner since October 2023.

Dr. Tong obtained bachelor’s degrees in biology sciences from the University of Science and Technology of China and in economics from Peking University, and he also obtained a doctoral degree in biochemistry and molecular biology from Chinese Academy of Sciences.

Mr. YANG JUN was appointed as the Director in April 2026. Mr. YANG served as an executive director at SC Lowy & Co. from October 2009 to August 2011. He worked as an investment director from August 2011 to January 2014 and served successively as the assistant to the general manager of investment, deputy general manager, and general manager of the Investment Department at Far East Horizon Limited, a company listed on the Stock Exchange (stock code: 3360), from January 2014 to April 2016.

Mr. YANG has been serving as managing director at Grand Flight Investment Management Co., Ltd. since June 2016. He has also been serving as a non-executive director at Peijia Medical Ltd., a company listed on the Stock Exchange (stock code: 9996), since August 2020.

Mr. YANG obtained a bachelor’s degree in electric engineering from Nanyang Technological University in Singapore, and he also obtained a master’s degree in business administration from Institut Europe´en d’Administration des Affaires in France.

Dr. Zhang was appointed as the Director in September 2023. Dr. Zhang served successively as senior researcher, project manager, senior project manager, and deputy R&D director of our Company from July 2021 to July 2023 and has been serving as the R&D director of our Company since July 2023.

Dr. Zhang obtained a bachelor’s degree in biology sciences from Jilin University, and she also obtained a doctoral degree from Center for Excellence in Molecular Cell Sciences of Chinese Academy of Sciences.

Dr. Liao was appointed as the Director in August 2025. He has been serving as the R&D director of our Company since October 2025.

Dr. Liao served successively as a postdoctoral fellow and an associate researcher at East China Normal University, respectively.

Dr. Liao obtained a bachelor’s degree in life science and technology from Wuhan University. He also obtained a doctoral degree through successive postgraduate and doctoral program in developmental biology from Center for Excellence in Molecular Cell Sciences of Chinese Academy of Sciences. He was awarded the First Prize of Shanghai Municipal Science and Technology Progress Award in April 2025 by the Science and Technology Commission of Shanghai Municipality.

As Chief Development and Technical Officer at YolTech, Dr. Emma Wang orchestrates the strategic advancement of the company’s core platforms and therapeutic programs. With over a decade of expertise in the pharmaceutical and biotech sectors, Emma previously spent more than five years specializing in mRNA/LNP drug product development and CMC strategy. At YolTech, she now integrates these disciplines, directing a multidisciplinary organization that spans R&D, CMC strategy, global manufacturing, regulatory affairs, and the transition into early-stage clinical trials. She holds a B.Eng and M.Eng in Chemical Engineering from McGill University in Canada and Ph.D. in Chemistry from Max Planck Institute for Polymer Research in Germany.

Bringing over 35 years of senior leadership experience in the biopharmaceutical industry, Dr. Moreau has held executive positions at Roche, Novartis, Sanofi, Bayer and UCB, where he led enterprise-level strategy, business transformation, and cross-border deals. Prior to joining YolTech, Dr. Moreau served as President of UCB China, overseeing a major restructuring and the divestment of legacy assets through strategic partnerships.

Dr. Moreau holds a Doctorate in Pharmaceutical and Biological Sciences from Rene Descartes University, an MBA from La Sorbonne University in France and graduated from the INSEAD Advanced Management Program and from the General Management Program at Harvard Business School.

Prof. Ott brings more than thirty years of experience in hepatology, gene, and cell therapy, moving early-stage innovations toward clinical application. He currently serves as Professor of Gastroenterology, Hepatology and Endocrinology at Hannover Medical School, where he leads the Center for Gene and Cell Therapy of Liver Diseases. His additional leadership roles include principal investigator at TWINCORE – Center for Experimental and Clinical Infection Research, and senior investigator at the REBIRTH Center for Translational Regenerative Medicine.

Prof. Ott’s pioneering work in liver gene therapy, base editing, and organoid engineering has yielded more than 200 peer-reviewed publications. His research has appeared in leading journals including Cell, Cell Stem Cell, Nature Communications, Gastroenterology, Gut, Journal of Hepatology, and Hepatology, with over 9,000 citations to date and an H-index of 48.